Literature DB >> 33387253

Resistance training improves cardiac function and cardiovascular autonomic control in doxorubicin-induced cardiotoxicity.

Larissa Andrade de Sá Feitosa1, Jéssica Dos Santos Carvalho2, Cácia Oliveira Dantas3, Diego Santos de Souza3, Carla Maria Lins de Vasconcelos3, Rodrigo Miguel-Dos-Santos3,4, Sandra Lauton-Santos3, Lucindo José Quíntans-Júnior3, Márcio Roberto Viana Santos3, Valter Joviniano de Santana-Filho3, André Sales Barreto2.   

Abstract

Doxorubicin (DOX) is an anticancer chemotherapy drug that is widely used in clinical practice. It is well documented that DOX impairs baroreflex responsiveness and left ventricular function and enhances sympathetic activity, cardiac sympathetic afferent reflexes and oxidative stress, which contribute to hemodynamic deterioration. Because resistance training (RT)-induced cardioprotection has been observed in other animal models, the objective of this study was to assess the effects of RT during DOX treatment on hemodynamics, arterial baroreflex, cardiac autonomic tone, left ventricular function and oxidative stress in rats with DOX-induced cardiotoxicity. Male Wistar rats were submitted to a RT protocol (3 sets of 10 repetitions, 40% of one-repetition maximum (1RM) of intensity, 3 times per week, for 8 weeks). The rats were separated into 3 groups: sedentary control, DOX sedentary (2.5 mg/kg of DOX intraperitoneal injection, once a week, for 6 weeks) and DOX + RT. After training or time control, the animals were anesthetized and 2 catheters were implanted for hemodynamic, arterial baroreflex and cardiac autonomic tone. Another group of animals was used to evaluate left ventricular function. We found that RT in DOX-treated rats decreased diastolic arterial pressure, heart rate, sympathetic tone and oxidative stress. In addition, RT increased arterial baroreflex sensitivity, vagal tone and left ventricular developed pressure in rats with DOX-induced cardiotoxicity. In summary, RT is a useful non-pharmacological strategy to attenuate DOX-induced cardiotoxicity.

Entities:  

Keywords:  Autonomic Nervous System; Baroreflex; Hemodynamic; Isolated Heart Preparation; Oxidative stress

Mesh:

Substances:

Year:  2021        PMID: 33387253     DOI: 10.1007/s12012-020-09627-w

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN: 1530-7905            Impact factor:   3.231


  36 in total

Review 1.  Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?

Authors:  Douglas B Sawyer; Xuyang Peng; Billy Chen; Laura Pentassuglia; Chee Chew Lim
Journal:  Prog Cardiovasc Dis       Date:  2010 Sep-Oct       Impact factor: 8.194

2.  Pretreatment hepatoprotective effect of regular aerobic training against hepatic toxicity induced by Doxorubicin in rats.

Authors:  Fatemeh Zolfagharzadeh; Valiollah Dabidi Roshan
Journal:  Asian Pac J Cancer Prev       Date:  2013

3.  Exercise and Doxorubicin Treatment Modulate Cardiac Mitochondrial Quality Control Signaling.

Authors:  I Marques-Aleixo; E Santos-Alves; J R Torrella; P J Oliveira; J Magalhães; A Ascensão
Journal:  Cardiovasc Toxicol       Date:  2018-02       Impact factor: 3.231

4.  Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity.

Authors:  Adam J Chicco; David S Hydock; Carole M Schneider; Reid Hayward
Journal:  J Appl Physiol (1985)       Date:  2005-10-06

5.  Physical exercise prior and during treatment reduces sub-chronic doxorubicin-induced mitochondrial toxicity and oxidative stress.

Authors:  Inês Marques-Aleixo; Estela Santos-Alves; Diogo Mariani; David Rizo-Roca; Ana I Padrão; Sílvia Rocha-Rodrigues; Ginés Viscor; J Ramon Torrella; Rita Ferreira; Paulo J Oliveira; José Magalhães; António Ascensão
Journal:  Mitochondrion       Date:  2014-11-07       Impact factor: 4.160

Review 6.  Doxorubicin cardiomyopathy.

Authors:  Kanu Chatterjee; Jianqing Zhang; Norman Honbo; Joel S Karliner
Journal:  Cardiology       Date:  2009-12-11       Impact factor: 1.869

7.  Central endothelin: effects on vasopressin and the arterial baroreflex in doxorubicin heart failure rats.

Authors:  Noreen F Rossi; Maria Maliszewska-Scislo; Haiping Chen
Journal:  Can J Physiol Pharmacol       Date:  2008-06       Impact factor: 2.273

Review 8.  Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.

Authors:  Giorgio Minotti; Pierantonio Menna; Emanuela Salvatorelli; Gaetano Cairo; Luca Gianni
Journal:  Pharmacol Rev       Date:  2004-06       Impact factor: 25.468

Review 9.  Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance.

Authors:  Hamdan S Al-Malky; Sameer E Al Harthi; Abdel-Moneim M Osman
Journal:  J Oncol Pharm Pract       Date:  2019-10-09       Impact factor: 1.809

10.  Enhanced sympathetic activity and cardiac sympathetic afferent reflex in rats with heart failure induced by adriamycin.

Authors:  Shujuan Zhang; Feng Zhang; Haijian Sun; Yebo Zhou; Ying Han
Journal:  J Biomed Res       Date:  2012-10-19
View more
  3 in total

Review 1.  Exercise Cardio-Oncology: Exercise as a Potential Therapeutic Modality in the Management of Anthracycline-Induced Cardiotoxicity.

Authors:  Dong-Woo Kang; Rebekah L Wilson; Cami N Christopher; Amber J Normann; Oscar Barnes; Jordan D Lesansee; Gyuhwan Choi; Christina M Dieli-Conwright
Journal:  Front Cardiovasc Med       Date:  2022-01-14

2.  Preventive aerobic training preserves sympathovagal function and improves DNA repair capacity of peripheral blood mononuclear cells in rats with cardiomyopathy.

Authors:  Paola Victória da Costa Ghignatti; Mariana Kras Borges Russo; Tiago Becker; Temenouga Nikolova Guecheva; Luciele Varaschini Teixeira; Alexandre Machado Lehnen; Maximiliano Isoppo Schaun; Natalia Motta Leguisamo
Journal:  Sci Rep       Date:  2022-04-19       Impact factor: 4.996

3.  Benefits of combined exercise training on arterial stiffness and blood pressure in spontaneously hypertensive rats treated or not with dexamethasone.

Authors:  Lidieli P Tardelli; Francine Duchatsch; Naiara A Herrera; Thalles Fernando R Ruiz; Luana U Pagan; Carlos A Vicentini; Katashi Okoshi; Sandra L Amaral
Journal:  Front Physiol       Date:  2022-08-15       Impact factor: 4.755

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.